유럽, 미국, 중국, 일본 급성 호흡곤란증후군(ARDS) 시장 – 2030년까지의 산업 동향 및 예측

TOC 요청 TOC 요청 분석가에게 문의 분석가에게 문의 지금 구매 지금 구매 구매하기 전에 문의 구매하기 전에 문의 무료 샘플 보고서 무료 샘플 보고서

유럽, 미국, 중국, 일본 급성 호흡곤란증후군(ARDS) 시장 – 2030년까지의 산업 동향 및 예측

  • Healthcare
  • Published Report
  • Jan 2023
  • Country Level
  • 350 Pages
  • 테이블 수: 234
  • 그림 수: 106

Europe Us China And Japan Acute Respiratory Distress Syndrome Ards Market

시장 규모 (USD 10억)

연평균 성장률 :  % Diagram

Diagram 예측 기간
2024 –2030
Diagram 시장 규모(기준 연도)
백만 달러
Diagram 시장 규모(예측 연도)
백만 달러
Diagram 연평균 성장률
%
Diagram주요 시장 플레이어
  • Dummy1
  • Dummy2
  • Dummy3
  • Dummy4
  • Dummy5

>유럽, 미국, 중국, 일본의 급성 호흡곤란증후군(ARDS) 시장, 원인별(코로나19, 패혈증, 유해물질 흡입, 중증 폐렴 등), 유형별(진단 및 치료), 투여 경로(경구, 비경구 및 기타), 최종 사용자(병원, 전문 병원, 가정 의료 및 기타), 유통 채널(직접 입찰, 병원 약국, 소매 약국 및 온라인 약국) - 2030년까지의 산업 동향 및 예측.

유럽, 미국, 중국, 일본 급성 호흡곤란증후군(ARDS) 시장 분석 및 통찰력

COVID-19 및 급성 호흡곤란증후군과 같은 감염성 및 호흡기 질환의 유병률이 증가하고 이러한 질환에 대한 백신 개발 및 치료 및 진단 제품에 대한 광범위한 초점이 시장 수요를 강화했습니다. 제품을 쉽게 공급하고 빠른 제조 시설을 위한 기술의 발전도 시장 성장에 기여하고 있습니다. 주요 시장 참여자는 이 중요한 기간 동안 제품 출시 및 승인에 매우 집중하고 있습니다. 또한 정부와 규제 기관은 급증하는 부상으로 인해 시장 참여자에게 제품 승인을 지원하고 있습니다.

유럽, 미국, 중국, 일본 급성 호흡곤란증후군(ARDS) 시장

유럽, 미국, 중국, 일본 급성 호흡곤란증후군(ARDS) 시장

유럽, 미국, 중국, 일본의 급성 호흡곤란증후군(ARDS) 시장은 지지적이며 질병을 감소시켜 개인의 회복과 성과를 개선하는 것을 목표로 합니다. Data Bridge Market Research는 유럽, 미국, 중국, 일본의 급성 호흡곤란증후군(ARDS) 시장이 2023년에서 2030년까지의 예측 기간 동안 9.9%의 CAGR로 성장할 것이라고 분석합니다.

보고서 메트릭

세부

예측 기간

2023년부터 2030년까지

기준 연도

2022

역사적 연도

2021 (2020-2015까지 사용자 정의 가능)

양적 단위

수익은 백만 달러, 가격은 미화로 표시

다루는 세그먼트

원인별(코로나19, 패혈증, 유해물질 흡입, 중증 폐렴 등), 유형별(진단 및 치료), 투여 경로(경구, 비경구 및 기타), 최종 사용자별(병원, 전문 병원, 가정 의료 및 기타), 유통 채널별(직접 입찰, 병원 약국, 소매 약국 및 온라인 약국)

국가 커버

 미국, 일본, 중국, 독일, 영국, 이탈리아, 프랑스, ​​스페인, 스위스, 러시아, 터키, 헝가리, 리투아니아, 오스트리아, 아일랜드, 노르웨이, 폴란드, 네덜란드 및 유럽의 나머지 지역

시장 참여자 포함

Drägerwerk AG & Co. KGaA, Fisher & Paykel Healthcare Limited., LivaNova PLC, Gilead Sciences, Inc., Fresenius SE & Co. KGaA, Besmed Health Business Corp., Armstrong Medical, Smiths Medical, ResMed, ALung Technologies, Inc., Medtronic, F. Hoffmann-La Roche Ltd, Hamilton Medical, nice Neotech Medical Systems Pvt. Ltd., Pfizer Inc., WEINMANN Emergency Medical Technology GmbH + Co. KG, NIPRO, Terumo Medical Corporation, Getinge AB., 및 EUROSETS 등

시장 정의

급성 호흡곤란증후군(ARDS)은 폐로 체액이 새어 들어가는 생명을 위협하는 폐 손상입니다. ARDS에 걸린 대부분의 사람들은 외상이나 COVID-19와 같은 질병으로 입원합니다. 이 증후군은 일반적으로 폐의 작고 탄력 있는 기낭인 폐포에 체액이 축적될 때 발생합니다. 이러한 체액 축적으로 인해 혈류에 도달하는 산소가 줄어듭니다. 이로 인해 장기가 정상적인 기능을 수행하는 데 필요한 산소를 충분히 얻지 못하게 됩니다. 다른 질병이 있는 사람들은 촉발된 부상이나 감염 후 몇 시간에서 며칠 이내에 ARDS를 발병합니다. 사망 위험은 나이가 들면서 증가하고 질병의 심각도에 따라 증후군에서 살아남은 환자는 힘들어집니다. 폐의 막낭에 손상을 입히는 심각한 질병이나 부상은 ARDS로 이어집니다. 해당 질병의 가장 흔한 근본 원인에는 패혈증, 유해 물질 흡입, 중증 폐렴, 머리, 가슴 또는 다른 심각한 부상, 코로나바이러스감염증 2019(COVID-19) 등이 있습니다.

유럽, 미국, 중국, 일본 급성 호흡곤란증후군(ARDS) 시장 동향

이 섹션에서는 시장 동인, 기회, 제약 및 과제를 이해하는 것을 다룹니다. 이 모든 내용은 아래에서 자세히 설명합니다.

운전자

  • 급성 폐손상의 유병률 및 발생률 증가

급성 폐 손상 환자는 노령 인구 증가, 패혈증 및 폐렴 환자 증가와 같은 여러 요인으로 인해 널리 보고되고 있습니다. 그러나 대부분의 사람들은 후기 단계에서만 폐 손상 및 급성 호흡 곤란 증후군 진단을 받습니다. 해당 질병은 폐가 손상된 환자에게 발생하는 빠르게 진행되는 질환으로 체액이 누출됩니다. 최근 몇 년 동안 COVID-19와 같은 다양한 호흡기 질환을 유발하는 바이러스가 출현함에 따라 급성 호흡 곤란 증후군 사례와 폐 손상의 수가 증가하고 있습니다.

따라서 급성 호흡곤란증후군의 발생률과 유병률은 계속 증가하고 있습니다. 이 질병은 전 세계적으로 주요 임상 문제로 널리 인식되어 왔으며, 높은 이환율과 사망률 부담을 안고 있습니다. 따라서 급성 폐 손상과 동반되는 급성 호흡곤란증후군의 유병률과 발생률이 증가하면서 유럽, 미국, 중국, 일본의 급성 호흡곤란증후군(ARDS) 시장이 성장할 것으로 예상됩니다.

  • 급성 호흡곤란증후군(ARDS)의 광범위한 위험 요소

급성 호흡곤란증후군에 대한 위험 요인은 엄청나게 다양합니다. 이 증후군에는 환경적 위험 요인과 개인적 위험 요인이 관련되어 있습니다. ARDS 환자는 다양한 정도의 폐동맥 혈관 수축으로 인해 혈액으로 충분한 산소를 공급하는 데 문제가 발생합니다. 따라서 일반적으로 인공호흡기를 사용하여 호흡해야 합니다. ARDS는 높은 사망률을 유발하고 이 치명적인 상태를 완화합니다. 다발성 장기 부전을 동반한 패혈증 증후군이 가장 흔한 사망 원인이고 호흡 부전이 두 번째입니다. 게다가 ARDS의 심각성은 중증 COVID-19 환자의 사망률과 상당히 관련이 있습니다.

ARDS는 외상을 포함한 여러 원인에 의해 유발될 수 있습니다. 다중 외상 후 ARDS의 위험 요인에는 외상성 뇌 및 흉부 손상, 쇼크의 심각도 및 지속 시간, 수혈된 혈액 제품 수, 주입된 결정체가 포함됩니다.

유럽, 미국, 중국, 일본 급성 호흡곤란증후군(ARDS) 시장

기회

  •  급성 호흡곤란증후군(ARDS)에 대한 인식 증가

 급성 호흡곤란증후군은 여러 가지 다른 원인이 있기 때문에 일반적으로 일반적인 사망 원인으로 무시됩니다. 진보된 기술적 치료와 상태에 대한 적절한 인식이 필요하면 급성 호흡곤란증후군 발생률을 상당히 줄일 수 있습니다. 시기적절한 진단과 예방이 예방 또는 더 빠른 회복에 중요하기 때문에 대중의 관심이 가장 중요합니다. 현재 정부와 기관은 폐 손상 연구 범위를 확대하여 급성 호흡곤란증후군의 1차 예방을 포함하고 증후군의 이환율이나 사망률을 줄였습니다.

다시 시작된 이니셔티브는 여전히 ARDS와 같은 심각한 폐 감염의 예방을 돕고 있으며, 생명공학 및 제약 회사가 치료법의 새로운 진전을 위한 연구를 혁신하도록 지원합니다. ARDS에 대한 적절하거나 구체적인 치료법은 없지만, 이 증후군에 대한 인식을 높이고 환자가 폐를 적시에 치유하도록 돕기 위해 노력하는 협회는 거의 없습니다.

다양한 의료 및 폐 관리 협회에서 시작한 이러한 새로운 이니셔티브 프로그램과 지원 치료 단위는 원인과 적절한 질병 관리에 대한 사람들의 인식을 높이고 있습니다. 따라서 다양한 협회를 통해 ARDS에 대한 인식을 높이면 향후 유럽, 미국, 중국 및 일본의 급성 호흡 곤란 증후군(ARDS) 시장 성장 기회가 향상됩니다.

제지/도전

  • 장비 및 치료 비용이 높음

급성 호흡곤란증후군은 광범위한 고급 치료 옵션을 제공받고 있지만, 평균 소득 계층에서는 장기 치료 비용을 감당하기 어렵습니다. 중환자 치료 및 집중 치료실 서비스 이용은 전 세계적으로 증가하고 있으며, 그 비싼 비용은 현재 의료 시스템에서 주요 관심사입니다. 급성 호흡곤란증후군 환자는 일반적으로 빈번한 화폐화 및 인공호흡기 사용과 함께 장기 입원이 필요하여 상당한 양의 의료 자원을 소모합니다. 이로 인해 장기 입원을 감당할 수 없는 대부분의 환자는 치료 초기 단계에서 퇴원합니다. 그러나 이로 인해 감염에서 새로운 합병증의 가능성과 취약성이 증가하여 추가적인 의료 자원과 치료가 필요합니다.

COVID-19 이후 유럽, 미국, 중국, 일본 급성 호흡곤란증후군(ARDS) 시장에 미치는 영향

COVID-19는 이 지역에서 급성 호흡곤란 증후군에 대한 수요가 증가함에 따라 시장 성장에 긍정적인 영향을 미쳤습니다. COVID-19 단계 동안 여러 사례가 무증상인 반면 COVID-19 사례의 20%는 입원이 필요한 심각한 과정을 거칩니다. COVID-19 질병의 중증 사례는 궁극적으로 ARDS와 폐렴으로 이어집니다. 이는 감염된 개인에게 치명적인 것으로 입증되었습니다. ARDS는 폐의 작은 기낭인 폐포를 손상시켜 폐 결함을 나타내므로 COVID-19 환자에서도 동일한 수준의 결함이 관찰되었습니다. 이로 인해 액체가 갑자기 유입되어 폐렴이 발생합니다. 따라서 COVID-19는 이 시장에 긍정적인 영향을 미쳤습니다.

최근 개발 사항

  • 2021년 5월, Medtronic은 SonarMed 기도 모니터링 시스템을 출시했습니다. 이 시스템은 음향 기술을 활용하여 기관 내 튜브 막힘을 확인합니다. 이를 통해 회사는 제품 포트폴리오를 늘리는 데 도움이 되었습니다.
  • 2020년 7월, F. Hoffman-La Roche Ltd는 SARS-CoV-2 신속 항체 검사를 출시했습니다. 이 검사는 SD Biosenseor, Inc.와 협력하여 출시되었습니다. 이를 통해 회사는 제품 포트폴리오를 늘리는 데 도움이 되었습니다.

유럽, 미국, 중국, 일본 급성 호흡곤란증후군(ARDS) 시장 범위

유럽, 미국, 중국, 일본의 급성 호흡곤란증후군(ARDS) 시장은 원인, 유형, 투여 경로, 최종 사용자, 유통 채널을 기준으로 5개 세그먼트로 분류됩니다. 세그먼트 간 성장은 틈새 성장 포켓과 시장에 접근하고 핵심 응용 분야와 타겟 시장의 차이점을 파악하기 위한 전략을 분석하는 데 도움이 됩니다.

원인

  • 코로나바이러스감염증 2019(COVID-19)
  • 부패
  • 유해물질 흡입
  • 중증 폐렴
  • 기타

유럽, 미국, 중국, 일본의 급성 호흡곤란증후군(ARDS) 시장은 원인에 따라 코로나바이러스감염증-19(COVID-19), 패혈증, 유해물질 흡입, 중증 폐렴 등으로 구분됩니다.

유형

  • 진단
  • 치료

유럽, 미국, 중국, 일본의 급성 호흡곤란증후군(ARDS) 시장은 유형에 따라 진단과 치료로 구분됩니다.

투여 경로

  • 경구
  • 비경구적
  • 기타

유럽, 미국, 중국, 일본의 급성 호흡곤란증후군(ARDS) 시장은 투여 경로를 기준으로 경구, 비경구 및 기타로 구분됩니다.

최종 사용자

  • 병원
  • 전문 클리닉
  • 홈 헬스케어
  • 기타

유럽, 미국, 중국, 일본의 급성 호흡곤란증후군(ARDS) 시장은 최종 사용자를 기준으로 병원, 전문 클리닉, 재택 건강관리 및 기타로 세분화됩니다.

유통 채널

  • 직접 입찰
  • 병원 약국
  • 소매 약국
  • 온라인 약국

유럽, 미국, 중국, 일본 급성 호흡곤란증후군(ARDS) 시장

유럽, 미국, 중국, 일본의 급성 호흡곤란증후군(ARDS) 시장은 유통 채널을 기준으로 직접 입찰, 병원 약국, 소매 약국, 온라인 약국으로 구분됩니다.

유럽, 미국, 중국, 일본 급성 호흡곤란증후군(ARDS) 시장 국가 분석/통찰력

유럽, 미국, 중국, 일본의 급성 호흡곤란증후군(ARDS) 시장을 분석하고, 위에 언급된 원인, 유형, 투여 경로, 최종 사용자, 유통 채널별로 시장 규모에 대한 통찰력과 추세를 제공합니다.

유럽, 미국, 중국, 일본의 급성 호흡곤란증후군(ARDS) 시장에서 다루는 국가는 미국, 일본, 중국, 독일, 영국, 이탈리아, 프랑스, ​​스페인, 스위스, 러시아, 터키, 헝가리, 리투아니아, 오스트리아, 아일랜드, 노르웨이, 폴란드, 네덜란드 및 기타 유럽 국가입니다.

미국 급성 호흡곤란증후군(ARDS) 시장은 급성 폐 손상의 유병률 증가와 ARDS가 있는 COVID-19 환자 풀의 증가로 인해 성장할 것으로 예상됩니다. 이는 미국 시장 성장을 촉진할 것으로 예상되는 주요 기여 요인입니다.

보고서의 국가 섹션은 또한 현재 및 미래 시장 추세에 영향을 미치는 개별 시장 영향 요인과 시장 규제의 변화를 제공합니다. 하류 및 상류 가치 사슬 분석, 기술 추세, 포터의 5가지 힘 분석, 사례 연구와 같은 데이터 포인트는 개별 국가의 시장 시나리오를 예측하는 데 사용되는 몇 가지 포인터입니다. 또한 브랜드의 존재 및 가용성과 지역 및 국내 브랜드와의 대규모 또는 희소한 경쟁으로 인해 직면한 과제, 국내 관세 및 무역 경로의 영향이 국가 데이터에 대한 예측 분석을 제공하는 동안 고려됩니다.

유럽, 미국, 중국, 일본 급성 호흡곤란증후군(ARDS) 시장

경쟁 환경 및 유럽, 미국, 중국, 일본의 급성 호흡곤란증후군(ARDS) 시장 점유율 분석

유럽, 미국, 중국, 일본의 급성 호흡곤란증후군(ARDS) 시장 경쟁 구도는 경쟁사에 대한 세부 정보를 제공합니다. 포함된 세부 정보에는 회사 개요, 회사 재무, 창출된 수익, 시장 잠재력, 연구 개발 투자, 새로운 시장 이니셔티브, 입지, 생산 현장 및 시설, 생산 용량, 회사의 강점과 약점, 제품 출시, 제품 폭과 범위, 응용 프로그램 우위가 포함됩니다. 위에 제공된 데이터 포인트는 유럽, 미국, 중국, 일본의 급성 호흡곤란증후군(ARDS) 시장에 대한 회사의 초점과만 관련이 있습니다.

시장에서 활동하는 주요 기업으로는 Drägerwerk AG & Co. KGaA, Fisher & Paykel Healthcare Limited., LivaNova PLC, Gilead Sciences, Inc., Fresenius SE & Co. KGaA, Besmed Health Business Corp., Armstrong Medical, Smiths Medical, ResMed, ALung Technologies, Inc., Medtronic, F. Hoffmann-La Roche Ltd, Hamilton Medical, nice Neotech Medical Systems Pvt. Ltd., Pfizer Inc., WEINMANN Emergency Medical Technology GmbH + Co. KG, NIPRO, Terumo Medical Corporation, Getinge AB., EUROSETS 등이 있습니다.


SKU-

세계 최초의 시장 정보 클라우드 보고서에 온라인으로 접속하세요

  • 대화형 데이터 분석 대시보드
  • 높은 성장 잠재력 기회를 위한 회사 분석 대시보드
  • 사용자 정의 및 질의를 위한 리서치 분석가 액세스
  • 대화형 대시보드를 통한 경쟁자 분석
  • 최신 뉴스, 업데이트 및 추세 분석
  • 포괄적인 경쟁자 추적을 위한 벤치마크 분석의 힘 활용
데모 요청

목차

1 INTRODUCTION

1.1 OBJECTIVES OF THE STUDY

1.2 MARKET DEFINITION

1.3 OVERVIEW OF EUROPE, U.S., CHINA, AND JAPAN ACUTE RESPIRATORY DISTRESS SYNDROME (ARDS) MARKET

1.4 LIMITATIONS

1.5 MARKETS COVERED

2 MARKET SEGMENTATION

2.1 MARKETS COVERED

2.2 GEOGRAPHICAL SCOPE

2.3 YEARS CONSIDERED FOR THE STUDY

2.4 CURRENCY AND PRICING

2.5 DBMR TRIPOD DATA VALIDATION MODEL

2.6 MULTIVARIATE MODELLING

2.7 CAUSE LIFELINE CURVE

2.8 PRIMARY INTERVIEWS WITH KEY OPINION LEADERS

2.9 DBMR MARKET POSITION GRID

2.1 MARKET END USER COVERAGE GRID

2.11 VENDOR SHARE ANALYSIS

2.12 SECONDARY SOURCES

2.13 ASSUMPTIONS

3 EXECUTIVE SUMMARY

4 PREMIUM INSIGHTS

4.1 PESTEL ANALYSIS

4.2 PORTER’S FIVE FORCES

4.3 ETIOLOGY BY GEOGRAPHY

4.3.1 ETIOLOGY IN U.S.

4.3.2 ETIOLOGY IN EUROPE

4.3.3 ETIOLOGY IN CHINA

4.3.4 ETIOLOGY IN JAPAN

4.4 ACUTE RESPIRATORY DISTRESS SYNDROME (ARDS) HEALTHCARE COST PER PATIENT BY GEOGRAPHY

4.5 INSURANCE REIMBURSEMENT

4.5.1 CENTER FOR MEDICARE SERVICES (CMS)–ELSO (EXTRACORPOREAL LIFE SUPPORT ORGANIZATION)

4.5.2 HEALTH RESOURCES AND SERVICES ADMINISTRATION

4.5.3 ABBOTT CODING GUIDE FOR ECMO

4.5.4 CENTRAL GOVERNMENT HEALTH SCHEME (CGHS)

4.5.5 CERN HEALTH INSURANCE SCHEME

4.5.6 AMERICAN SOCIETY OF CLINICAL ONCOLOGY (ASCO) – (MEDICARE & MEDICAID)

4.5.7 AMERICAN HOSPITAL ASSOCIATION

4.5.8 CONCLUSION

4.6 PIPELINE ANALYSIS

5 EUROPE, U.S., CHINA, AND JAPAN ACUTE RESPIRATORY DISTRESS SYNDROME (ARDS) MARKET: REGULATIONS

5.1 REGULATION IN U.S.:

5.2 LABELING OF MODIFIED DEVICES

5.3 REGULATION IN EUROPE:

5.4 REGULATION IN CHINA:

5.5 REGULATION IN JAPAN:

6 MARKET OVERVIEW

6.1 DRIVERS

6.1.1 INCREASING PREVALENCE AND INCIDENCE OF ACUTE LUNG INJURY

6.1.2 WIDE RANGE OF RISK FACTORS FOR ACUTE RESPIRATORY DISTRESS SYNDROME

6.1.3 ACCELERATION IN PATIENT POOL OF COVID-19 WITH ARDS

6.1.4 RISING RATE OF AIR POLLUTION AND LIFESTYLE-RELATED DISEASES

6.1.5 INCREASING ACCIDENT RATES AND TRAUMA-CAUSING ARDS

6.2 RESTRAINTS

6.2.1 COMPLICATIONS ASSOCIATED WITH TREATMENTS

6.2.2 HIGH COST OF DEVICE AND TREATMENTS

6.2.3 LACK OF SKILLED WORKFORCE

6.3 OPPORTUNITIES

6.3.1 GROWING GERIATRIC POPULATION

6.3.2 RISING HEALTHCARE EXPENDITURE

6.3.3 STRATEGIC INITIATIVES BY MARKET PLAYERS

6.3.4 INCREASING AWARENESS REGARDING ACUTE RESPIRATORY DISTRESS SYNDROME(ARDS)

6.4 CHALLENGES

6.4.1 STRINGENT RULES & REGULATIONS

6.4.2 MULTIPLE CHALLENGES FACED BY ICU NURSES

7 EUROPE, U.S., CHINA, AND JAPAN ACUTE RESPIRATORY DISTRESS SYNDROME (ARDS) MARKET, BY CAUSE

7.1 OVERVIEW

7.2 CORONAVIRUS DISEASE 2019 (COVID-19)

7.3 SEPSIS

7.4 INHALATION OF HARMFUL SUBSTANCES

7.5 SEVERE PNEUMONIA

7.6 OTHERS

8 EUROPE, U.S., CHINA, AND JAPAN ACUTE RESPIRATORY DISTRESS SYNDROME (ARDS) MARKET, BY TYPE

8.1 OVERVIEW

8.2 DIAGNOSIS

8.2.1 IMAGING TESTS

8.2.1.1 CHEST X-RAY

8.2.1.2 CT SCAN

8.2.1.3 ULTRASOUND

8.2.1.4 OTHERS

8.2.2 BLOOD TEST

8.2.3 RESPIRATORY RATE

8.2.4 SPO2 TEST

8.2.5 OTHERS

8.3 TREATMENT

8.3.1 MECHANICAL VENTILATION

8.3.1.1 HIGH-FLOW NASAL O2

8.3.1.2 BI-LEVEL POSITIVE AIRWAY PRESSURE

8.3.1.3 CONTINUOUS POSITIVE AIRWAY PRESSURE

8.3.1.4 PRONE POSITIVE VENTILATION

8.3.1.5 OTHERS

8.3.2 CORTICOSTEROIDS

8.3.2.1 METHYLPREDNISOLONE

8.3.2.2 DEXAMETHASONE

8.3.2.3 OTHERS

8.3.3 ANTIVIRAL MEDICATION

8.3.3.1 REMDESIVIR

8.3.3.2 COMBINATION DRUGS

8.3.3.3 OTHERS

8.3.4 EXTRACORPOREAL MEMBRANE OXYGENATION (ECMO)

8.3.5 TOCILIZUMAB

8.3.6 OTHERS

9 EUROPE, U.S., CHINA, AND JAPAN ACUTE RESPIRATORY DISTRESS SYNDROME (ARDS) MARKET, BY ROUTE OF ADMINISTRATION

9.1 OVERVIEW

9.2 PARENTERAL

9.2.1 INTRAVENOUS

9.2.2 INTRAMUSCULAR

9.3 ORAL

9.4 OTHERS

10 EUROPE, U.S., CHINA, AND JAPAN ACUTE RESPIRATORY DISTRESS SYNDROME (ARDS) MARKET, BY END USER

10.1 OVERVIEW

10.2 HOSPITALS

10.3 SPECIALTY CLINICS

10.4 HOME HEALTHCARE

10.5 OTHERS

11 EUROPE, U.S., CHINA, AND JAPAN ACUTE RESPIRATORY DISTRESS SYNDROME (ARDS) MARKET, BY DISTRIBUTION CHANNEL

11.1 OVERVIEW

11.2 DIRECT TENDER

11.3 HOSPITAL PHARMACY

11.4 RETAIL PHARMACY

11.5 ONLINE PHARMACY

12 EUROPE

12.1 GERMANY

12.2 FRANCE

12.3 U.K.

12.4 ITALY

12.5 SPAIN

12.6 TURKEY

12.7 HUNGARY

12.8 NETHERLANDS

12.9 SWITZERLAND

12.1 AUSTRIA

12.11 LITHUANIA

12.12 POLAND

12.13 RUSSIA

12.14 IRELAND

12.15 NORWAY

12.16 REST OF EUROPE

13 EUROPE, US, CHINA, AND JAPAN ACUTE RESPIRATORY DISTRESS SYNDROME (ARDS) MARKET: COMPANY LANDSCAPE

13.1 COMPANY SHARE ANALYSIS: U.S.

13.2 COMPANY SHARE ANALYSIS: EUROPE

13.3 COMPANY SHARE ANALYSIS: JAPAN

13.4 COMPANY SHARE ANALYSIS: CHINA

14 SWOT ANALYSIS

15 COMPANY PROFILE

15.1 GILEAD SCIENCES INC.

15.1.1 COMPANY SNAPSHOT

15.1.2 REVENUS ANALYSIS

15.1.3 PRODUCT PORTFOLIO

15.1.4 RECENT DEVELOPMENT

15.2 TERUMO CORPORATION

15.2.1 COMPANY SNAPSHOT

15.2.2 REVENUS ANALYSIS

15.2.3 PRODUCT PORTFOLIO

15.2.4 RECENT DEVELOPMENT

15.3 GETINGE AB

15.3.1 COMPANY SNAPSHOT

15.3.2 REVENUS ANALYSIS

15.3.3 PRODUCT PORTFOLIO

15.3.4 RECENT DEVELOPMENT

15.4 LIVANOVA PLC

15.4.1 COMPANY SNAPSHOT

15.4.2 REVENUE ANALYSIS

15.4.3 PRODUCT PORTFOLIO

15.4.4 RECENT DEVELOPMENTS

15.5 MEDTRONIC

15.5.1 COMPANY SNAPSHOT

15.5.2 REVENUE ANALYSIS

15.5.3 PRODUCT PORTFOLIO

15.5.4 RECENT DEVELOPMENTS

15.6 ALUNG TECHNOLOGIES, INC

15.6.1 COMPANY SNAPSHOT

15.6.2 PRODUCT PORTFOLIO

15.6.3 RECENT DEVELOPMENT

15.7 ARMSTRONG MEDICAL

15.7.1 COMPANY SNAPSHOT

15.7.2 PRODUCT PORTFOLIO

15.7.3 RECENT DEVELOPMENT

15.8 BESMED HEALTH BUSINESS CORP.

15.8.1 COMPANY SNAPSHOT

15.8.2 PRODUCT PORTFOLIO

15.8.3 RECENT DEVELOPMENTS

15.9 DRÄGERWERK AG & CO. KGAA

15.9.1 COMPANY SNAPSHOT

15.9.2 REVENUE ANALYSIS

15.9.3 PRODUCT PORTFOLIO

15.9.4 RECENT DEVELOPMENTS

15.1 EUROSETS

15.10.1 COMPANY SNAPSHOT

15.10.2 PRODUCT PORTFOLIO

15.10.3 RECENT DEVELOPMENT

15.11 F. HOFFMANN-LA ROCHE LTD

15.11.1 COMPANY SNAPSHOT

15.11.2 RECENT ANALYSIS

15.11.3 PRODUCT PORTFOLIO

15.11.4 RECENT DEVELOPMENTS

15.12 FISHER & PAYKEL HEALTHCARE LIMITED

15.12.1 COMPANY SNAPSHOT

15.12.2 REVENUE ANALYSIS

15.12.3 PRODUCT PORTFOLIO

15.12.4 RECENT DEVELOPMENTS

15.13 FRESENIUS SE & CO. KGAA

15.13.1 COMPANY SNAPSHOT

15.13.2 REVENUS ANALYSIS

15.13.3 PRODUCT PORTFOLIO

15.13.4 RECENT DEVELOPMENTS

15.14 HAMILTON MEDICAL

15.14.1 COMPANY SNAPSHOT

15.14.2 PRODUCT PORTFOLIO

15.14.3 RECENT DEVELOPMENT

15.15 NICE NEOTECH MEDICAL SYSTEMS PVT.LTD.

15.15.1 COMPANY SNAPSHOT

15.15.2 PRODUCT PORTFOLIO

15.15.3 RECENT DEVELOPMENT

15.16 NIPRO

15.16.1 COMPANY SNAPSHOT

15.16.2 REVENUS ANALYSIS

15.16.3 PRODUCT PORTFOLIO

15.16.4 RECENT DEVELOPMENT

15.17 PFIZER INC.

15.17.1 COMPANY SNAPSHOT

15.17.2 REVENUS ANALYSIS

15.17.3 PRODUCT PORTFOLIO

15.17.4 RECENT DEVELOPMENT

15.18 RESMED

15.18.1 COMPANY SNAPSHOT

15.18.2 REVENUE ANALYSIS

15.18.3 PRODUCT PORTFOLIO

15.18.4 RECENT DEVELOPMENT

15.19 SMITHS MEDICAL

15.19.1 COMPANY SNAPSHOT

15.19.2 REVENUS ANALYSIS

15.19.3 PRODUCT PORTFOLIO

15.19.4 RECENT DEVELOPMENTS

15.2 WEINMANN EMERGENCY MEDICAL TECHNOLOGY GMBH + CO. KG

15.20.1 COMPANY SNAPSHOT

15.20.2 PRODUCT PORTFOLIO

15.20.3 RECENT DEVELOPMENT

16 QUESTIONNAIRE

17 RELATED REPORTS

표 목록

TABLE 1 HEALTHCARE COST FOR ACUTE RESPIRATORY DISTRESS SYNDROME (ARDS) ON THE BASIS OF SEVERITY BY COUNTRY IS GIVEN BELOW IN USD:

TABLE 2 EUROPE, U.S., CHINA, AND JAPAN ACUTE RESPIRATORY DISTRESS SYNDROME (ARDS) MARKET: PIPELINE ANALYSIS

TABLE 3 REGULATION FOR VENTILATORS AND RESPIRATORY DEVICES AS PER FDA

TABLE 4 REGULATION FOR THE USE OF VENTILATOR AND ANESTHESIA GAS MACHINE BREATHING CIRCUIT DEVICES

TABLE 5 EUROPE ACUTE RESPIRATORY DISTRESS SYNDROME (ARDS) MARKET, BY CAUSE, 2021-2030 (USD MILLION)

TABLE 6 U.S. ACUTE RESPIRATORY DISTRESS SYNDROME (ARDS) MARKET, BY CAUSE, 2021-2030 (USD MILLION)

TABLE 7 CHINA ACUTE RESPIRATORY DISTRESS SYNDROME (ARDS) MARKET, BY CAUSE, 2021-2030 (USD MILLION)

TABLE 8 JAPAN ACUTE RESPIRATORY DISTRESS SYNDROME (ARDS) MARKET, BY CAUSE, 2021-2030 (USD MILLION)

TABLE 9 EUROPE ACUTE RESPIRATORY DISTRESS SYNDROME (ARDS) MARKET, BY TYPE, 2021-2030 (USD MILLION)

TABLE 10 U.S. ACUTE RESPIRATORY DISTRESS SYNDROME (ARDS) MARKET, BY TYPE, 2021-2030 (USD MILLION)

TABLE 11 CHINA ACUTE RESPIRATORY DISTRESS SYNDROME (ARDS) MARKET, BY TYPE, 2021-2030 (USD MILLION)

TABLE 12 JAPAN ACUTE RESPIRATORY DISTRESS SYNDROME (ARDS) MARKET, BY TYPE, 2021-2030 (USD MILLION)

TABLE 13 EUROPE DIAGNOSIS IN ACUTE RESPIRATORY DISTRESS SYNDROME (ARDS) MARKET, BY TYPE, 2021-2030 (USD MILLION)

TABLE 14 U.S. DIAGNOSIS IN ACUTE RESPIRATORY DISTRESS SYNDROME (ARDS) MARKET, BY TYPE, 2021-2030 (USD MILLION)

TABLE 15 CHINA DIAGNOSIS IN ACUTE RESPIRATORY DISTRESS SYNDROME (ARDS) MARKET, BY TYPE, 2021-2030 (USD MILLION)

TABLE 16 JAPAN DIAGNOSIS IN ACUTE RESPIRATORY DISTRESS SYNDROME (ARDS) MARKET, BY TYPE, 2021-2030 (USD MILLION)

TABLE 17 EUROPE IMAGING TESTS IN ACUTE RESPIRATORY DISTRESS SYNDROME (ARDS) MARKET, BY TYPE, 2021-2030 (USD MILLION)

TABLE 18 U.S. IMAGING TESTS IN ACUTE RESPIRATORY DISTRESS SYNDROME (ARDS) MARKET, BY TYPE, 2021-2030 (USD MILLION)

TABLE 19 CHINA IMAGING TESTS IN ACUTE RESPIRATORY DISTRESS SYNDROME (ARDS) MARKET, BY TYPE, 2021-2030 (USD MILLION)

TABLE 20 JAPAN IMAGING TESTS IN ACUTE RESPIRATORY DISTRESS SYNDROME (ARDS) MARKET, BY TYPE, 2021-2030 (USD MILLION)

TABLE 21 EUROPE TREATMENT IN ACUTE RESPIRATORY DISTRESS SYNDROME (ARDS) MARKET, BY TYPE, 2021-2030(USD MILLION)

TABLE 22 U.S. TREATMENT IN ACUTE RESPIRATORY DISTRESS SYNDROME (ARDS) MARKET, BY TYPE, 2021-2030 (USD MILLION)

TABLE 23 CHINA TREATMENT IN ACUTE RESPIRATORY DISTRESS SYNDROME (ARDS) MARKET, BY TYPE, 2021-2030 (USD MILLION)

TABLE 24 JAPAN TREATMENT IN ACUTE RESPIRATORY DISTRESS SYNDROME (ARDS) MARKET, BY TYPE, 2021-2030 (USD MILLION)

TABLE 25 EUROPE MECHANICAL VENTILATION IN ACUTE RESPIRATORY DISTRESS SYNDROME (ARDS) MARKET, BY TYPE, 2021-2030 (USD MILLION)

TABLE 26 U.S. MECHANICAL VENTILATION IN ACUTE RESPIRATORY DISTRESS SYNDROME (ARDS) MARKET, BY TYPE, 2021-2030 (USD MILLION)

TABLE 27 CHINA MECHANICAL VENTILATION IN ACUTE RESPIRATORY DISTRESS SYNDROME (ARDS) MARKET, BY TYPE, 2021-2030 (USD MILLION)

TABLE 28 JAPAN MECHANICAL VENTILATION IN ACUTE RESPIRATORY DISTRESS SYNDROME (ARDS) MARKET, BY TYPE, 2021-2030 (USD MILLION)

TABLE 29 EUROPE CORTICOSTEROIDS IN ACUTE RESPIRATORY DISTRESS SYNDROME (ARDS) MARKET, BY TYPE, 2021-2030 (USD MILLION)

TABLE 30 U.S. CORTICOSTEROIDS IN ACUTE RESPIRATORY DISTRESS SYNDROME (ARDS) MARKET, BY TYPE, 2021-2030 (USD MILLION)

TABLE 31 CHINA CORTICOSTEROIDS IN ACUTE RESPIRATORY DISTRESS SYNDROME (ARDS) MARKET, BY TYPE, 2021-2030 (USD MILLION)

TABLE 32 JAPAN CORTICOSTEROIDS IN ACUTE RESPIRATORY DISTRESS SYNDROME (ARDS) MARKET, BY TYPE, 2021-2030 (USD MILLION)

TABLE 33 EUROPE ANTIVIRAL MEDICATION IN ACUTE RESPIRATORY DISTRESS SYNDROME (ARDS) MARKET, BY TYPE, 2021-2030 (USD MILLION)

TABLE 34 U.S. ANTIVIRAL MEDICATION IN ACUTE RESPIRATORY DISTRESS SYNDROME (ARDS) MARKET, BY TYPE, 2021-2030 (USD MILLION)

TABLE 35 CHINA ANTIVIRAL MEDICATION IN ACUTE RESPIRATORY DISTRESS SYNDROME (ARDS) MARKET, BY TYPE, 2021-2030 (USD MILLION)

TABLE 36 JAPAN ANTIVIRAL MEDICATION IN ACUTE RESPIRATORY DISTRESS SYNDROME (ARDS) MARKET, BY TYPE, 2021-2030 (USD MILLION)

TABLE 37 EUROPE ACUTE RESPIRATORY DISTRESS SYNDROME (ARDS) MARKET, BY ROUTE OF ADMINISTRATION, 2021-2030 (USD MILLION)

TABLE 38 U.S. ACUTE RESPIRATORY DISTRESS SYNDROME (ARDS) MARKET, BY ROUTE OF ADMINISTRATION, 2021-2030 (USD MILLION)

TABLE 39 CHINA ACUTE RESPIRATORY DISTRESS SYNDROME (ARDS) MARKET, BY ROUTE OF ADMINISTRATION, 2021-2030 (USD MILLION)

TABLE 40 JAPAN ACUTE RESPIRATORY DISTRESS SYNDROME (ARDS) MARKET, BY ROUTE OF ADMINISTRATION, 2021-2030 (USD MILLION)

TABLE 41 EUROPE PARENTRAL IN ACUTE RESPIRATORY DISTRESS SYNDROME (ARDS) MARKET, BY ROUTE OF ADMINISTRATION, 2021-2030 (USD MILLION)

TABLE 42 U.S. PARENTRAL IN ACUTE RESPIRATORY DISTRESS SYNDROME (ARDS) MARKET, BY ROUTE OF ADMINISTRATION, 2021-2030 (USD MILLION)

TABLE 43 CHINA PARENTRAL IN ACUTE RESPIRATORY DISTRESS SYNDROME (ARDS) MARKET, BY ROUTE OF ADMINISTRATION, 2021-2030 (USD MILLION)

TABLE 44 JAPAN PARENTRAL IN ACUTE RESPIRATORY DISTRESS SYNDROME (ARDS) MARKET, BY ROUTE OF ADMINISTRATION, 2021-2030 (USD MILLION)

TABLE 45 EUROPE ACUTE RESPIRATORY DISTRESS SYNDROME (ARDS) MARKET, BY END USER, 2021-2030 (USD MILLION)

TABLE 46 U.S. ACUTE RESPIRATORY DISTRESS SYNDROME (ARDS) MARKET, BY END USER, 2021-2030 (USD MILLION)

TABLE 47 CHINA ACUTE RESPIRATORY DISTRESS SYNDROME (ARDS) MARKET, BY END USER, 2021-2030 (USD MILLION)

TABLE 48 JAPAN ACUTE RESPIRATORY DISTRESS SYNDROME (ARDS) MARKET, BY END USER, 2021-2030 (USD MILLION)

TABLE 49 EUROPE ACUTE RESPIRATORY DISTRESS SYNDROME (ARDS) MARKET, BY DISTRIBUTION CHANNEL, 2021-2030 (USD MILLION)

TABLE 50 U.S. ACUTE RESPIRATORY DISTRESS SYNDROME (ARDS) MARKET, BY DISTRIBUTION CHANNEL, 2021-2030 (USD MILLION)

TABLE 51 CHINA ACUTE RESPIRATORY DISTRESS SYNDROME (ARDS) MARKET, BY DISTRIBUTION CHANNEL, 2021-2030 (USD MILLION)

TABLE 52 JAPAN ACUTE RESPIRATORY DISTRESS SYNDROME (ARDS) MARKET, BY DISTRIBUTION CHANNEL, 2021-2030 (USD MILLION)

TABLE 53 EUROPE ACUTE RESPIRATORY DISTRESS SYNDROME (ARDS) MARKET, BY COUNTRY, 2021-2030 (USD MILLION)

TABLE 54 GERMANY ACUTE RESPIRATORY DISTRESS SYNDROME (ARDS) MARKET, BY CAUSE, 2021-2030 (USD MILLION)

TABLE 55 GERMANY ACUTE RESPIRATORY DISTRESS SYNDROME (ARDS) MARKET, BY TYPE, 2021-2030 (USD MILLION)

TABLE 56 GERMANY DIAGNOSIS IN ACUTE RESPIRATORY DISTRESS SYNDROME (ARDS) MARKET, BY TYPE, 2021-2030 (USD MILLION)

TABLE 57 GERMANY IMAGING TESTS IN ACUTE RESPIRATORY DISTRESS SYNDROME (ARDS) MARKET, BY TYPE, 2021-2030 (USD MILLION)

TABLE 58 GERMANY TREATMENT IN ACUTE RESPIRATORY DISTRESS SYNDROME (ARDS) MARKET, BY TYPE, 2021-2030 (USD MILLION)

TABLE 59 GERMANY ANTIVIRAL MEDICATION IN ACUTE RESPIRATORY DISTRESS SYNDROME (ARDS) MARKET, BY TYPE, 2021-2030 (USD MILLION)

TABLE 60 GERMANY CORTICOSTEROIDS IN ACUTE RESPIRATORY DISTRESS SYNDROME (ARDS) MARKET, BY TYPE, 2021-2030 (USD MILLION)

TABLE 61 GERMANY MECHANICAL VENTILATION IN ACUTE RESPIRATORY DISTRESS SYNDROME (ARDS) MARKET, BY TYPE, 2021-2030 (USD MILLION)

TABLE 62 GERMANY ACUTE RESPIRATORY DISTRESS SYNDROME (ARDS) MARKET, BY ROUTE OF ADMINISTRATION, 2021-2030 (USD MILLION)

TABLE 63 GERMANY PARENTERAL IN ACUTE RESPIRATORY DISTRESS SYNDROME (ARDS) MARKET, BY ROUTE OF ADMINISTRATION, 2021-2030 (USD MILLION)

TABLE 64 GERMANY ACUTE RESPIRATORY DISTRESS SYNDROME (ARDS) MARKET, BY END USER, 2021-2030 (USD MILLION)

TABLE 65 GERMANY ACUTE RESPIRATORY DISTRESS SYNDROME (ARDS) MARKET, BY DISTRIBUTION CHANNEL, 2021-2030 (USD MILLION)

TABLE 66 FRANCE ACUTE RESPIRATORY DISTRESS SYNDROME (ARDS) MARKET, BY CAUSE, 2021-2030 (USD MILLION)

TABLE 67 FRANCE ACUTE RESPIRATORY DISTRESS SYNDROME (ARDS) MARKET, BY TYPE, 2021-2030 (USD MILLION)

TABLE 68 FRANCE DIAGNOSIS IN ACUTE RESPIRATORY DISTRESS SYNDROME (ARDS) MARKET, BY TYPE, 2021-2030 (USD MILLION)

TABLE 69 FRANCE IMAGING TESTS IN ACUTE RESPIRATORY DISTRESS SYNDROME (ARDS) MARKET, BY TYPE, 2021-2030 (USD MILLION)

TABLE 70 FRANCE TREATMENT IN ACUTE RESPIRATORY DISTRESS SYNDROME (ARDS) MARKET, BY TYPE, 2021-2030 (USD MILLION)

TABLE 71 FRANCE ANTIVIRAL MEDICATION IN ACUTE RESPIRATORY DISTRESS SYNDROME (ARDS) MARKET, BY TYPE, 2021-2030 (USD MILLION)

TABLE 72 FRANCE CORTICOSTEROIDS IN ACUTE RESPIRATORY DISTRESS SYNDROME (ARDS) MARKET, BY TYPE, 2021-2030 (USD MILLION)

TABLE 73 FRANCE MECHANICAL VENTILATION IN ACUTE RESPIRATORY DISTRESS SYNDROME (ARDS) MARKET, BY TYPE, 2021-2030 (USD MILLION)

TABLE 74 FRANCE ACUTE RESPIRATORY DISTRESS SYNDROME (ARDS) MARKET, BY ROUTE OF ADMINISTRATION, 2021-2030 (USD MILLION)

TABLE 75 FRANCE PARENTERAL IN ACUTE RESPIRATORY DISTRESS SYNDROME (ARDS) MARKET, BY ROUTE OF ADMINISTRATION, 2021-2030 (USD MILLION)

TABLE 76 FRANCE ACUTE RESPIRATORY DISTRESS SYNDROME (ARDS) MARKET, BY END USER, 2021-2030 (USD MILLION)

TABLE 77 FRANCE ACUTE RESPIRATORY DISTRESS SYNDROME (ARDS) MARKET, BY DISTRIBUTION CHANNEL, 2021-2030 (USD MILLION)

TABLE 78 U.K. ACUTE RESPIRATORY DISTRESS SYNDROME (ARDS) MARKET, BY CAUSE, 2021-2030 (USD MILLION)

TABLE 79 U.K. ACUTE RESPIRATORY DISTRESS SYNDROME (ARDS) MARKET, BY TYPE, 2021-2030 (USD MILLION)

TABLE 80 U.K. DIAGNOSIS IN ACUTE RESPIRATORY DISTRESS SYNDROME (ARDS) MARKET, BY TYPE, 2021-2030 (USD MILLION)

TABLE 81 U.K. IMAGING TESTS IN ACUTE RESPIRATORY DISTRESS SYNDROME (ARDS) MARKET, BY TYPE, 2021-2030 (USD MILLION)

TABLE 82 U.K. TREATMENT IN ACUTE RESPIRATORY DISTRESS SYNDROME (ARDS) MARKET, BY TYPE, 2021-2030 (USD MILLION)

TABLE 83 U.K. ANTIVIRAL MEDICATION IN ACUTE RESPIRATORY DISTRESS SYNDROME (ARDS) MARKET, BY TYPE, 2021-2030 (USD MILLION)

TABLE 84 U.K. CORTICOSTEROIDS IN ACUTE RESPIRATORY DISTRESS SYNDROME (ARDS) MARKET, BY TYPE, 2021-2030 (USD MILLION)

TABLE 85 U.K. MECHANICAL VENTILATION IN ACUTE RESPIRATORY DISTRESS SYNDROME (ARDS) MARKET, BY TYPE, 2021-2030 (USD MILLION)

TABLE 86 U.K. ACUTE RESPIRATORY DISTRESS SYNDROME (ARDS) MARKET, BY ROUTE OF ADMINISTRATION, 2021-2030 (USD MILLION)

TABLE 87 U.K. PARENTERAL IN ACUTE RESPIRATORY DISTRESS SYNDROME (ARDS) MARKET, BY ROUTE OF ADMINISTRATION, 2021-2030 (USD MILLION)

TABLE 88 U.K. ACUTE RESPIRATORY DISTRESS SYNDROME (ARDS) MARKET, BY END USER, 2021-2030 (USD MILLION)

TABLE 89 U.K. ACUTE RESPIRATORY DISTRESS SYNDROME (ARDS) MARKET, BY DISTRIBUTION CHANNEL, 2021-2030 (USD MILLION)

TABLE 90 ITALY ACUTE RESPIRATORY DISTRESS SYNDROME (ARDS) MARKET, BY CAUSE, 2021-2030 (USD MILLION)

TABLE 91 ITALY ACUTE RESPIRATORY DISTRESS SYNDROME (ARDS) MARKET, BY TYPE, 2021-2030 (USD MILLION)

TABLE 92 ITALY DIAGNOSIS IN ACUTE RESPIRATORY DISTRESS SYNDROME (ARDS) MARKET, BY TYPE, 2021-2030 (USD MILLION)

TABLE 93 ITALY IMAGING TESTS IN ACUTE RESPIRATORY DISTRESS SYNDROME (ARDS) MARKET, BY TYPE, 2021-2030 (USD MILLION)

TABLE 94 ITALY TREATMENT IN ACUTE RESPIRATORY DISTRESS SYNDROME (ARDS) MARKET, BY TYPE, 2021-2030 (USD MILLION)

TABLE 95 ITALY ANTIVIRAL MEDICATION IN ACUTE RESPIRATORY DISTRESS SYNDROME (ARDS) MARKET, BY TYPE, 2021-2030 (USD MILLION)

TABLE 96 ITALY CORTICOSTEROIDS IN ACUTE RESPIRATORY DISTRESS SYNDROME (ARDS) MARKET, BY TYPE, 2021-2030 (USD MILLION)

TABLE 97 ITALY MECHANICAL VENTILATION IN ACUTE RESPIRATORY DISTRESS SYNDROME (ARDS) MARKET, BY TYPE, 2021-2030 (USD MILLION)

TABLE 98 ITALY ACUTE RESPIRATORY DISTRESS SYNDROME (ARDS) MARKET, BY ROUTE OF ADMINISTRATION, 2021-2030 (USD MILLION)

TABLE 99 ITALY PARENTERAL IN ACUTE RESPIRATORY DISTRESS SYNDROME (ARDS) MARKET, BY ROUTE OF ADMINISTRATION, 2021-2030 (USD MILLION)

TABLE 100 ITALY ACUTE RESPIRATORY DISTRESS SYNDROME (ARDS) MARKET, BY END USER, 2021-2030 (USD MILLION)

TABLE 101 ITALY ACUTE RESPIRATORY DISTRESS SYNDROME (ARDS) MARKET, BY DISTRIBUTION CHANNEL, 2021-2030 (USD MILLION)

TABLE 102 SPAIN ACUTE RESPIRATORY DISTRESS SYNDROME (ARDS) MARKET, BY CAUSE, 2021-2030 (USD MILLION)

TABLE 103 SPAIN ACUTE RESPIRATORY DISTRESS SYNDROME (ARDS) MARKET, BY TYPE, 2021-2030 (USD MILLION)

TABLE 104 SPAIN DIAGNOSIS IN ACUTE RESPIRATORY DISTRESS SYNDROME (ARDS) MARKET, BY TYPE, 2021-2030 (USD MILLION)

TABLE 105 SPAIN IMAGING TESTS IN ACUTE RESPIRATORY DISTRESS SYNDROME (ARDS) MARKET, BY TYPE, 2021-2030 (USD MILLION)

TABLE 106 SPAIN TREATMENT IN ACUTE RESPIRATORY DISTRESS SYNDROME (ARDS) MARKET, BY TYPE, 2021-2030 (USD MILLION)

TABLE 107 SPAIN ANTIVIRAL MEDICATION IN ACUTE RESPIRATORY DISTRESS SYNDROME (ARDS) MARKET, BY TYPE, 2021-2030 (USD MILLION)

TABLE 108 SPAIN CORTICOSTEROIDS IN ACUTE RESPIRATORY DISTRESS SYNDROME (ARDS) MARKET, BY TYPE, 2021-2030 (USD MILLION)

TABLE 109 SPAIN MECHANICAL VENTILATION IN ACUTE RESPIRATORY DISTRESS SYNDROME (ARDS) MARKET, BY TYPE, 2021-2030 (USD MILLION)

TABLE 110 SPAIN ACUTE RESPIRATORY DISTRESS SYNDROME (ARDS) MARKET, BY ROUTE OF ADMINISTRATION, 2021-2030 (USD MILLION)

TABLE 111 SPAIN PARENTERAL IN ACUTE RESPIRATORY DISTRESS SYNDROME (ARDS) MARKET, BY ROUTE OF ADMINISTRATION, 2021-2030 (USD MILLION)

TABLE 112 SPAIN ACUTE RESPIRATORY DISTRESS SYNDROME (ARDS) MARKET, BY END USER, 2021-2030 (USD MILLION)

TABLE 113 SPAIN ACUTE RESPIRATORY DISTRESS SYNDROME (ARDS) MARKET, BY DISTRIBUTION CHANNEL, 2021-2030 (USD MILLION)

TABLE 114 TURKEY ACUTE RESPIRATORY DISTRESS SYNDROME (ARDS) MARKET, BY CAUSE, 2021-2030 (USD MILLION)

TABLE 115 TURKEY ACUTE RESPIRATORY DISTRESS SYNDROME (ARDS) MARKET, BY TYPE, 2021-2030 (USD MILLION)

TABLE 116 TURKEY DIAGNOSIS IN ACUTE RESPIRATORY DISTRESS SYNDROME (ARDS) MARKET, BY TYPE, 2021-2030 (USD MILLION)

TABLE 117 TURKEY IMAGING TESTS IN ACUTE RESPIRATORY DISTRESS SYNDROME (ARDS) MARKET, BY TYPE, 2021-2030 (USD MILLION)

TABLE 118 TURKEY TREATMENT IN ACUTE RESPIRATORY DISTRESS SYNDROME (ARDS) MARKET, BY TYPE, 2021-2030 (USD MILLION)

TABLE 119 TURKEY ANTIVIRAL MEDICATION IN ACUTE RESPIRATORY DISTRESS SYNDROME (ARDS) MARKET, BY TYPE, 2021-2030 (USD MILLION)

TABLE 120 TURKEY CORTICOSTEROIDS IN ACUTE RESPIRATORY DISTRESS SYNDROME (ARDS) MARKET, BY TYPE, 2021-2030 (USD MILLION)

TABLE 121 TURKEY MECHANICAL VENTILATION IN ACUTE RESPIRATORY DISTRESS SYNDROME (ARDS) MARKET, BY TYPE, 2021-2030 (USD MILLION)

TABLE 122 TURKEY ACUTE RESPIRATORY DISTRESS SYNDROME (ARDS) MARKET, BY ROUTE OF ADMINISTRATION, 2021-2030 (USD MILLION)

TABLE 123 TURKEY PARENTERAL IN ACUTE RESPIRATORY DISTRESS SYNDROME (ARDS) MARKET, BY ROUTE OF ADMINISTRATION, 2021-2030 (USD MILLION

TABLE 124 TURKEY ACUTE RESPIRATORY DISTRESS SYNDROME (ARDS) MARKET, BY END USER, 2021-2030 (USD MILLION)

TABLE 125 TURKEY ACUTE RESPIRATORY DISTRESS SYNDROME (ARDS) MARKET, BY DISTRIBUTION CHANNEL, 2021-2030 (USD MILLION)

TABLE 126 HUNGARY ACUTE RESPIRATORY DISTRESS SYNDROME (ARDS) MARKET, BY CAUSE, 2021-2030 (USD MILLION)

TABLE 127 HUNGARY ACUTE RESPIRATORY DISTRESS SYNDROME (ARDS) MARKET, BY TYPE, 2021-2030 (USD MILLION)

TABLE 128 HUNGARY DIAGNOSIS IN ACUTE RESPIRATORY DISTRESS SYNDROME (ARDS) MARKET, BY TYPE, 2021-2030 (USD MILLION)

TABLE 129 HUNGARY IMAGING TESTS IN ACUTE RESPIRATORY DISTRESS SYNDROME (ARDS) MARKET, BY TYPE, 2021-2030 (USD MILLION)

TABLE 130 HUNGARY TREATMENT IN ACUTE RESPIRATORY DISTRESS SYNDROME (ARDS) MARKET, BY TYPE, 2021-2030 (USD MILLION)

TABLE 131 HUNGARY ANTIVIRAL MEDICATION IN ACUTE RESPIRATORY DISTRESS SYNDROME (ARDS) MARKET, BY TYPE, 2021-2030 (USD MILLION)

TABLE 132 HUNGARY CORTICOSTEROIDS IN ACUTE RESPIRATORY DISTRESS SYNDROME (ARDS) MARKET, BY TYPE, 2021-2030 (USD MILLION)

TABLE 133 HUNGARY MECHANICAL VENTILATION IN ACUTE RESPIRATORY DISTRESS SYNDROME (ARDS) MARKET, BY TYPE, 2021-2030 (USD MILLION)

TABLE 134 HUNGARY ACUTE RESPIRATORY DISTRESS SYNDROME (ARDS) MARKET, BY ROUTE OF ADMINISTRATION, 2021-2030 (USD MILLION)

TABLE 135 HUNGARY PARENTERAL IN ACUTE RESPIRATORY DISTRESS SYNDROME (ARDS) MARKET, BY ROUTE OF ADMINISTRATION, 2021-2030 (USD MILLION)

TABLE 136 HUNGARY ACUTE RESPIRATORY DISTRESS SYNDROME (ARDS) MARKET, BY END USER, 2021-2030 (USD MILLION)

TABLE 137 HUNGARY ACUTE RESPIRATORY DISTRESS SYNDROME (ARDS) MARKET, BY DISTRIBUTION CHANNEL, 2021-2030 (USD MILLION)

TABLE 138 NETHERLANDS ACUTE RESPIRATORY DISTRESS SYNDROME (ARDS) MARKET, BY CAUSE, 2021-2030 (USD MILLION)

TABLE 139 NETHERLANDS ACUTE RESPIRATORY DISTRESS SYNDROME (ARDS) MARKET, BY TYPE, 2021-2030 (USD MILLION)

TABLE 140 NETHERLANDS DIAGNOSIS IN ACUTE RESPIRATORY DISTRESS SYNDROME (ARDS) MARKET, BY TYPE, 2021-2030 (USD MILLION)

TABLE 141 NETHERLANDS IMAGING TESTS IN ACUTE RESPIRATORY DISTRESS SYNDROME (ARDS) MARKET, BY TYPE, 2021-2030 (USD MILLION)

TABLE 142 NETHERLANDS TREATMENT IN ACUTE RESPIRATORY DISTRESS SYNDROME (ARDS) MARKET, BY TYPE, 2021-2030 (USD MILLION)

TABLE 143 NETHERLANDS ANTIVIRAL MEDICATION IN ACUTE RESPIRATORY DISTRESS SYNDROME (ARDS) MARKET, BY TYPE, 2021-2030 (USD MILLION)

TABLE 144 NETHERLANDS CORTICOSTEROIDS IN ACUTE RESPIRATORY DISTRESS SYNDROME (ARDS) MARKET, BY TYPE, 2021-2030 (USD MILLION)

TABLE 145 NETHERLANDS MECHANICAL VENTILATION IN ACUTE RESPIRATORY DISTRESS SYNDROME (ARDS) MARKET, BY TYPE, 2021-2030 (USD MILLION)

TABLE 146 NETHERLANDS ACUTE RESPIRATORY DISTRESS SYNDROME (ARDS) MARKET, BY ROUTE OF ADMINISTRATION, 2021-2030 (USD MILLION)

TABLE 147 NETHERLANDS PARENTERAL IN ACUTE RESPIRATORY DISTRESS SYNDROME (ARDS) MARKET, BY ROUTE OF ADMINISTRATION, 2021-2030 (USD MILLION)

TABLE 148 NETHERLANDS ACUTE RESPIRATORY DISTRESS SYNDROME (ARDS) MARKET, BY END USER, 2021-2030 (USD MILLION)

TABLE 149 NETHERLANDS ACUTE RESPIRATORY DISTRESS SYNDROME (ARDS) MARKET, BY DISTRIBUTION CHANNEL, 2021-2030 (USD MILLION)

TABLE 150 SWITZERLAND ACUTE RESPIRATORY DISTRESS SYNDROME (ARDS) MARKET, BY CAUSE, 2021-2030 (USD MILLION)

TABLE 151 SWITZERLAND ACUTE RESPIRATORY DISTRESS SYNDROME (ARDS) MARKET, BY TYPE, 2021-2030 (USD MILLION)

TABLE 152 SWITZERLAND DIAGNOSIS IN ACUTE RESPIRATORY DISTRESS SYNDROME (ARDS) MARKET, BY TYPE, 2021-2030 (USD MILLION)

TABLE 153 SWITZERLAND IMAGING TESTS IN ACUTE RESPIRATORY DISTRESS SYNDROME (ARDS) MARKET, BY TYPE, 2021-2030 (USD MILLION)

TABLE 154 SWITZERLAND TREATMENT IN ACUTE RESPIRATORY DISTRESS SYNDROME (ARDS) MARKET, BY TYPE, 2021-2030 (USD MILLION)

TABLE 155 SWITZERLAND ANTIVIRAL MEDICATION IN ACUTE RESPIRATORY DISTRESS SYNDROME (ARDS) MARKET, BY TYPE, 2021-2030 (USD MILLION)

TABLE 156 SWITZERLAND CORTICOSTEROIDS IN ACUTE RESPIRATORY DISTRESS SYNDROME (ARDS) MARKET, BY TYPE, 2021-2030 (USD MILLION)

TABLE 157 SWITZERLAND MECHANICAL VENTILATION IN ACUTE RESPIRATORY DISTRESS SYNDROME (ARDS) MARKET, BY TYPE, 2021-2030 (USD MILLION)

TABLE 158 SWITZERLAND ACUTE RESPIRATORY DISTRESS SYNDROME (ARDS) MARKET, BY ROUTE OF ADMINISTRATION, 2021-2030 (USD MILLION)

TABLE 159 SWITZERLAND PARENTERAL IN ACUTE RESPIRATORY DISTRESS SYNDROME (ARDS) MARKET, BY ROUTE OF ADMINISTRATION, 2021-2030 (USD MILLION)

TABLE 160 SWITZERLAND ACUTE RESPIRATORY DISTRESS SYNDROME (ARDS) MARKET, BY END USER, 2021-2030 (USD MILLION)

TABLE 161 SWITZERLAND ACUTE RESPIRATORY DISTRESS SYNDROME (ARDS) MARKET, BY DISTRIBUTION CHANNEL, 2021-2030 (USD MILLION)

TABLE 162 AUSTRIA ACUTE RESPIRATORY DISTRESS SYNDROME (ARDS) MARKET, BY CAUSE, 2021-2030 (USD MILLION)

TABLE 163 AUSTRIA ACUTE RESPIRATORY DISTRESS SYNDROME (ARDS) MARKET, BY TYPE, 2021-2030 (USD MILLION)

TABLE 164 AUSTRIA DIAGNOSIS IN ACUTE RESPIRATORY DISTRESS SYNDROME (ARDS) MARKET, BY TYPE, 2021-2030 (USD MILLION)

TABLE 165 AUSTRIA IMAGING TESTS IN ACUTE RESPIRATORY DISTRESS SYNDROME (ARDS) MARKET, BY TYPE, 2021-2030 (USD MILLION)

TABLE 166 AUSTRIA TREATMENT IN ACUTE RESPIRATORY DISTRESS SYNDROME (ARDS) MARKET, BY TYPE, 2021-2030 (USD MILLION)

TABLE 167 AUSTRIA ANTIVIRAL MEDICATION IN ACUTE RESPIRATORY DISTRESS SYNDROME (ARDS) MARKET, BY TYPE, 2021-2030 (USD MILLION)

TABLE 168 AUSTRIA CORTICOSTEROIDS IN ACUTE RESPIRATORY DISTRESS SYNDROME (ARDS) MARKET, BY TYPE, 2021-2030 (USD MILLION)

TABLE 169 AUSTRIA MECHANICAL VENTILATION IN ACUTE RESPIRATORY DISTRESS SYNDROME (ARDS) MARKET, BY TYPE, 2021-2030 (USD MILLION)

TABLE 170 AUSTRIA ACUTE RESPIRATORY DISTRESS SYNDROME (ARDS) MARKET, BY ROUTE OF ADMINISTRATION, 2021-2030 (USD MILLION)

TABLE 171 AUSTRIA PARENTERAL IN ACUTE RESPIRATORY DISTRESS SYNDROME (ARDS) MARKET, BY ROUTE OF ADMINISTRATION, 2021-2030 (USD MILLION)

TABLE 172 AUSTRIA ACUTE RESPIRATORY DISTRESS SYNDROME (ARDS) MARKET, BY END USER, 2021-2030 (USD MILLION)

TABLE 173 AUSTRIA ACUTE RESPIRATORY DISTRESS SYNDROME (ARDS) MARKET, BY DISTRIBUTION CHANNEL, 2021-2030 (USD MILLION)

TABLE 174 LITHUANIA ACUTE RESPIRATORY DISTRESS SYNDROME (ARDS) MARKET, BY CAUSE, 2021-2030 (USD MILLION)

TABLE 175 LITHUANIA ACUTE RESPIRATORY DISTRESS SYNDROME (ARDS) MARKET, BY TYPE, 2021-2030 (USD MILLION)

TABLE 176 LITHUANIA DIAGNOSIS IN ACUTE RESPIRATORY DISTRESS SYNDROME (ARDS) MARKET, BY TYPE, 2021-2030 (USD MILLION)

TABLE 177 LITHUANIA IMAGING TESTS IN ACUTE RESPIRATORY DISTRESS SYNDROME (ARDS) MARKET, BY TYPE, 2021-2030 (USD MILLION)

TABLE 178 LITHUANIA TREATMENT IN ACUTE RESPIRATORY DISTRESS SYNDROME (ARDS) MARKET, BY TYPE, 2021-2030 (USD MILLION)

TABLE 179 LITHUANIA ANTIVIRAL MEDICATION IN ACUTE RESPIRATORY DISTRESS SYNDROME (ARDS) MARKET, BY TYPE, 2021-2030 (USD MILLION)

TABLE 180 LITHUANIA CORTICOSTEROIDS IN ACUTE RESPIRATORY DISTRESS SYNDROME (ARDS) MARKET, BY TYPE, 2021-2030 (USD MILLION)

TABLE 181 LITHUANIA MECHANICAL VENTILATION IN ACUTE RESPIRATORY DISTRESS SYNDROME (ARDS) MARKET, BY TYPE, 2021-2030 (USD MILLION)

TABLE 182 LITHUANIA ACUTE RESPIRATORY DISTRESS SYNDROME (ARDS) MARKET, BY ROUTE OF ADMINISTRATION, 2021-2030 (USD MILLION)

TABLE 183 LITHUANIA PARENTERAL IN ACUTE RESPIRATORY DISTRESS SYNDROME (ARDS) MARKET, BY ROUTE OF ADMINISTRATION, 2021-2030 (USD MILLION)

TABLE 184 LITHUANIA ACUTE RESPIRATORY DISTRESS SYNDROME (ARDS) MARKET, BY END USER, 2021-2030 (USD MILLION)

TABLE 185 LITHUANIA ACUTE RESPIRATORY DISTRESS SYNDROME (ARDS) MARKET, BY DISTRIBUTION CHANNEL, 2021-2030 (USD MILLION)

TABLE 186 POLAND ACUTE RESPIRATORY DISTRESS SYNDROME (ARDS) MARKET, BY CAUSE, 2021-2030 (USD MILLION)

TABLE 187 POLAND ACUTE RESPIRATORY DISTRESS SYNDROME (ARDS) MARKET, BY TYPE, 2021-2030 (USD MILLION)

TABLE 188 POLAND DIAGNOSIS IN ACUTE RESPIRATORY DISTRESS SYNDROME (ARDS) MARKET, BY TYPE, 2021-2030 (USD MILLION)

TABLE 189 POLAND IMAGING TESTS IN ACUTE RESPIRATORY DISTRESS SYNDROME (ARDS) MARKET, BY TYPE, 2021-2030 (USD MILLION)

TABLE 190 POLAND TREATMENT IN ACUTE RESPIRATORY DISTRESS SYNDROME (ARDS) MARKET, BY TYPE, 2021-2030 (USD MILLION)

TABLE 191 POLAND ANTIVIRAL MEDICATION IN ACUTE RESPIRATORY DISTRESS SYNDROME (ARDS) MARKET, BY TYPE, 2021-2030 (USD MILLION)

TABLE 192 POLAND CORTICOSTEROIDS IN ACUTE RESPIRATORY DISTRESS SYNDROME (ARDS) MARKET, BY TYPE, 2021-2030 (USD MILLION)

TABLE 193 POLAND MECHANICAL VENTILATION IN ACUTE RESPIRATORY DISTRESS SYNDROME (ARDS) MARKET, BY TYPE, 2021-2030 (USD MILLION)

TABLE 194 POLAND ACUTE RESPIRATORY DISTRESS SYNDROME (ARDS) MARKET, BY ROUTE OF ADMINISTRATION, 2021-2030 (USD MILLION)

TABLE 195 POLAND PARENTERAL IN ACUTE RESPIRATORY DISTRESS SYNDROME (ARDS) MARKET, BY ROUTE OF ADMINISTRATION, 2021-2030 (USD MILLION)

TABLE 196 POLAND ACUTE RESPIRATORY DISTRESS SYNDROME (ARDS) MARKET, BY END USER, 2021-2030 (USD MILLION)

TABLE 197 POLAND ACUTE RESPIRATORY DISTRESS SYNDROME (ARDS) MARKET, BY DISTRIBUTION CHANNEL, 2021-2030 (USD MILLION)

TABLE 198 RUSSIA ACUTE RESPIRATORY DISTRESS SYNDROME (ARDS) MARKET, BY CAUSE, 2021-2030 (USD MILLION)

TABLE 199 RUSSIA ACUTE RESPIRATORY DISTRESS SYNDROME (ARDS) MARKET, BY TYPE, 2021-2030 (USD MILLION)

TABLE 200 RUSSIA DIAGNOSIS IN ACUTE RESPIRATORY DISTRESS SYNDROME (ARDS) MARKET, BY TYPE, 2021-2030 (USD MILLION)

TABLE 201 RUSSIA IMAGING TESTS IN ACUTE RESPIRATORY DISTRESS SYNDROME (ARDS) MARKET, BY TYPE, 2021-2030 (USD MILLION)

TABLE 202 RUSSIA TREATMENT IN ACUTE RESPIRATORY DISTRESS SYNDROME (ARDS) MARKET, BY TYPE, 2021-2030 (USD MILLION)

TABLE 203 RUSSIA ANTIVIRAL MEDICATION IN ACUTE RESPIRATORY DISTRESS SYNDROME (ARDS) MARKET, BY TYPE, 2021-2030 (USD MILLION)

TABLE 204 RUSSIA CORTICOSTEROIDS IN ACUTE RESPIRATORY DISTRESS SYNDROME (ARDS) MARKET, BY TYPE, 2021-2030 (USD MILLION)

TABLE 205 RUSSIA MECHANICAL VENTILATION IN ACUTE RESPIRATORY DISTRESS SYNDROME (ARDS) MARKET, BY TYPE, 2021-2030 (USD MILLION)

TABLE 206 RUSSIA ACUTE RESPIRATORY DISTRESS SYNDROME (ARDS) MARKET, BY ROUTE OF ADMINISTRATION, 2021-2030 (USD MILLION)

TABLE 207 RUSSIA PARENTERAL IN ACUTE RESPIRATORY DISTRESS SYNDROME (ARDS) MARKET, BY ROUTE OF ADMINISTRATION, 2021-2030 (USD MILLION)

TABLE 208 RUSSIA ACUTE RESPIRATORY DISTRESS SYNDROME (ARDS) MARKET, BY END USER, 2021-2030 (USD MILLION)

TABLE 209 RUSSIA ACUTE RESPIRATORY DISTRESS SYNDROME (ARDS) MARKET, BY DISTRIBUTION CHANNEL, 2021-2030 (USD MILLION)

TABLE 210 IRELAND ACUTE RESPIRATORY DISTRESS SYNDROME (ARDS) MARKET, BY CAUSE, 2021-2030 (USD MILLION)

TABLE 211 IRELAND ACUTE RESPIRATORY DISTRESS SYNDROME (ARDS) MARKET, BY TYPE, 2021-2030 (USD MILLION)

TABLE 212 IRELAND DIAGNOSIS IN ACUTE RESPIRATORY DISTRESS SYNDROME (ARDS) MARKET, BY TYPE, 2021-2030 (USD MILLION)

TABLE 213 IRELAND IMAGING TESTS IN ACUTE RESPIRATORY DISTRESS SYNDROME (ARDS) MARKET, BY TYPE, 2021-2030 (USD MILLION)

TABLE 214 IRELAND TREATMENT IN ACUTE RESPIRATORY DISTRESS SYNDROME (ARDS) MARKET, BY TYPE, 2021-2030 (USD MILLION)

TABLE 215 IRELAND ANTIVIRAL MEDICATION IN ACUTE RESPIRATORY DISTRESS SYNDROME (ARDS) MARKET, BY TYPE, 2021-2030 (USD MILLION)

TABLE 216 IRELAND CORTICOSTEROIDS IN ACUTE RESPIRATORY DISTRESS SYNDROME (ARDS) MARKET, BY TYPE, 2021-2030 (USD MILLION)

TABLE 217 IRELAND MECHANICAL VENTILATION IN ACUTE RESPIRATORY DISTRESS SYNDROME (ARDS) MARKET, BY TYPE, 2021-2030 (USD MILLION)

TABLE 218 IRELAND ACUTE RESPIRATORY DISTRESS SYNDROME (ARDS) MARKET, BY ROUTE OF ADMINISTRATION, 2021-2030 (USD MILLION)

TABLE 219 IRELAND PARENTERAL IN ACUTE RESPIRATORY DISTRESS SYNDROME (ARDS) MARKET, BY ROUTE OF ADMINISTRATION, 2021-2030 (USD MILLION)

TABLE 220 IRELAND ACUTE RESPIRATORY DISTRESS SYNDROME (ARDS) MARKET, BY END USER, 2021-2030 (USD MILLION)

TABLE 221 IRELAND ACUTE RESPIRATORY DISTRESS SYNDROME (ARDS) MARKET, BY DISTRIBUTION CHANNEL, 2021-2030 (USD MILLION)

TABLE 222 NORWAY ACUTE RESPIRATORY DISTRESS SYNDROME (ARDS) MARKET, BY CAUSE, 2021-2030 (USD MILLION)

TABLE 223 NORWAY ACUTE RESPIRATORY DISTRESS SYNDROME (ARDS) MARKET, BY TYPE, 2021-2030 (USD MILLION)

TABLE 224 NORWAY DIAGNOSIS IN ACUTE RESPIRATORY DISTRESS SYNDROME (ARDS) MARKET, BY TYPE, 2021-2030 (USD MILLION)

TABLE 225 NORWAY IMAGING TESTS IN ACUTE RESPIRATORY DISTRESS SYNDROME (ARDS) MARKET, BY TYPE, 2021-2030 (USD MILLION)

TABLE 226 NORWAY TREATMENT IN ACUTE RESPIRATORY DISTRESS SYNDROME (ARDS) MARKET, BY TYPE, 2021-2030 (USD MILLION)

TABLE 227 NORWAY ANTIVIRAL MEDICATION IN ACUTE RESPIRATORY DISTRESS SYNDROME (ARDS) MARKET, BY TYPE, 2021-2030 (USD MILLION)

TABLE 228 NORWAY CORTICOSTEROIDS IN ACUTE RESPIRATORY DISTRESS SYNDROME (ARDS) MARKET, BY TYPE, 2021-2030 (USD MILLION)

TABLE 229 NORWAY MECHANICAL VENTILATION IN ACUTE RESPIRATORY DISTRESS SYNDROME (ARDS) MARKET, BY TYPE, 2021-2030 (USD MILLION)

TABLE 230 NORWAY ACUTE RESPIRATORY DISTRESS SYNDROME (ARDS) MARKET, BY ROUTE OF ADMINISTRATION, 2021-2030 (USD MILLION)

TABLE 231 NORWAY PARENTERAL IN ACUTE RESPIRATORY DISTRESS SYNDROME (ARDS) MARKET, BY ROUTE OF ADMINISTRATION, 2021-2030 (USD MILLION)

TABLE 232 NORWAY ACUTE RESPIRATORY DISTRESS SYNDROME (ARDS) MARKET, BY END USER, 2021-2030 (USD MILLION)

TABLE 233 NORWAY ACUTE RESPIRATORY DISTRESS SYNDROME (ARDS) MARKET, BY DISTRIBUTION CHANNEL, 2021-2030 (USD MILLION)

TABLE 234 REST OF EUROPE ACUTE RESPIRATORY DISTRESS SYNDROME (ARDS) MARKET, BY CAUSE, 2021-2030 (USD MILLION)

그림 목록

FIGURE 1 EUROPE, U.S., CHINA, AND JAPAN ACUTE RESPIRATORY DISTRESS SYNDROME (ARDS) MARKET: SEGMENTATION

FIGURE 2 EUROPE, U.S., CHINA, AND JAPAN ACUTE RESPIRATORY DISTRESS SYNDROME (ARDS) MARKET: DATA TRIANGULATION

FIGURE 3 EUROPE, U.S., CHINA, AND JAPAN ACUTE RESPIRATORY DISTRESS SYNDROME (ARDS) MARKET: DROC ANALYSIS

FIGURE 4 EUROPE, U.S., CHINA, AND JAPAN ACUTE RESPIRATORY DISTRESS SYNDROME (ARDS) MARKET: GLOBAL VS REGIONAL MARKET ANALYSIS

FIGURE 5 EUROPE, U.S., CHINA, AND JAPAN ACUTE RESPIRATORY DISTRESS SYNDROME (ARDS) MARKET: COMPANY RESEARCH ANALYSIS

FIGURE 6 EUROPE, U.S., CHINA, AND JAPAN ACUTE RESPIRATORY DISTRESS SYNDROME (ARDS) MARKET: INTERVIEW DEMOGRAPHICS

FIGURE 7 EUROPE, U.S., CHINA, AND JAPAN ACUTE RESPIRATORY DISTRESS SYNDROME (ARDS) MARKET: DBMR MARKET POSITION GRID

FIGURE 8 EUROPE, U.S., CHINA, AND JAPAN ACUTE RESPIRATORY DISTRESS SYNDROME (ARDS) MARKET: END USER COVERAGE GRID

FIGURE 9 EUROPE, U.S., CHINA, AND JAPAN ACUTE RESPIRATORY DISTRESS SYNDROME (ARDS) MARKET: VENDOR SHARE ANALYSIS

FIGURE 10 EUROPE, U.S., CHINA, AND JAPAN ACUTE RESPIRATORY DISTRESS SYNDROME (ARDS) MARKET: SEGMENTATION

FIGURE 11 ACCELERATION IN THE PATIENT POOL OF COVID-19 WITH ARDS IS EXPECTED TO DRIVE THE EUROPE, U.S., CHINA, AND JAPAN ACUTE RESPIRATORY DISTRESS SYNDROME (ARDS) MARKET IN THE FORECAST PERIOD OF 2023 TO 2030

FIGURE 12 CORONAVIRUS DISEASE 2019 (COVID-19) SEGMENT IS EXPECTED TO ACCOUNT FOR THE LARGEST SHARE OF THE EUROPE ACUTE RESPIRATORY DISTRESS SYNDROME (ARDS) MARKET IN 2023 & 2030

FIGURE 13 CORONAVIRUS DISEASE 2019 (COVID-19) SEGMENT IS EXPECTED TO ACCOUNT FOR THE LARGEST SHARE OF THE U.S.ACUTE RESPIRATORY DISTRESS SYNDROME (ARDS) MARKET IN 2023 & 2030

FIGURE 14 CORONAVIRUS DISEASE 2019 (COVID-19) SEGMENT IS EXPECTED TO ACCOUNT FOR THE LARGEST SHARE OF THE CHINA ACUTE RESPIRATORY DISTRESS SYNDROME (ARDS) MARKET IN 2023 & 2030

FIGURE 15 CORONAVIRUS DISEASE 2019 (COVID-19) SEGMENT IS EXPECTED TO ACCOUNT FOR THE LARGEST SHARE OF THE JAPAN ACUTE RESPIRATORY DISTRESS SYNDROME (ARDS) MARKET IN 2023 & 2030

FIGURE 16 MOST COMMON PRIMARY CAUSES OF DEATH IN ARDS PATIENTS IN U.S. COUNTRY

FIGURE 17 DRIVERS, RESTRAINTS, OPPORTUNITIES, AND CHALLENGES OF EUROPE, U.S., CHINA, AND JAPAN ACUTE RESPIRATORY DISTRESS SYNDROME (ARDS) MARKET

FIGURE 18 EUROPE ACUTE RESPIRATORY DISTRESS SYNDROME (ARDS) MARKET, BY CAUSE, 2022

FIGURE 19 EUROPE ACUTE RESPIRATORY DISTRESS SYNDROME (ARDS) MARKET: BY CAUSE, 2023-2030 (USD MILLION)

FIGURE 20 EUROPE ACUTE RESPIRATORY DISTRESS SYNDROME (ARDS) MARKET: BY CAUSE, CAGR (2023-2030)

FIGURE 21 EUROPE ACUTE RESPIRATORY DISTRESS SYNDROME (ARDS) MARKET: BY CAUSE, LIFELINE CURVE

FIGURE 22 U.S. ACUTE RESPIRATORY DISTRESS SYNDROME (ARDS) MARKET, BY CAUSE, 2022

FIGURE 23 U.S. ACUTE RESPIRATORY DISTRESS SYNDROME (ARDS) MARKET: BY CAUSE, 2023-2030 (USD MILLION)

FIGURE 24 U.S. ACUTE RESPIRATORY DISTRESS SYNDROME (ARDS) MARKET: BY CAUSE, CAGR (2023-2030)

FIGURE 25 U.S. ACUTE RESPIRATORY DISTRESS SYNDROME (ARDS) MARKET: BY CAUSE, LIFELINE CURVE

FIGURE 26 CHINA ACUTE RESPIRATORY DISTRESS SYNDROME (ARDS) MARKET, BY CAUSE, 2022

FIGURE 27 CHINA ACUTE RESPIRATORY DISTRESS SYNDROME (ARDS) MARKET: BY CAUSE, 2023-2030 (USD MILLION)

FIGURE 28 CHINA ACUTE RESPIRATORY DISTRESS SYNDROME (ARDS) MARKET: BY CAUSE, CAGR (2023-2030)

FIGURE 29 CHINA ACUTE RESPIRATORY DISTRESS SYNDROME (ARDS) MARKET: BY CAUSE, LIFELINE CURVE

FIGURE 30 JAPAN ACUTE RESPIRATORY DISTRESS SYNDROME (ARDS) MARKET, BY CAUSE, 2022

FIGURE 31 JAPAN ACUTE RESPIRATORY DISTRESS SYNDROME (ARDS) MARKET: BY CAUSE, 2023-2030 (USD MILLION)

FIGURE 32 JAPAN ACUTE RESPIRATORY DISTRESS SYNDROME (ARDS) MARKET: BY CAUSE, CAGR (2023-2030)

FIGURE 33 JAPAN ACUTE RESPIRATORY DISTRESS SYNDROME (ARDS) MARKET: BY CAUSE, LIFELINE CURVE

FIGURE 34 EUROPE ACUTE RESPIRATORY DISTRESS SYNDROME (ARDS) MARKET, BY TYPE, 2022

FIGURE 35 EUROPE ACUTE RESPIRATORY DISTRESS SYNDROME (ARDS) MARKET: BY TYPE, 2023-2030 (USD MILLION)

FIGURE 36 EUROPE ACUTE RESPIRATORY DISTRESS SYNDROME (ARDS) MARKET: BY TYPE, CAGR (2023-2030)

FIGURE 37 EUROPE ACUTE RESPIRATORY DISTRESS SYNDROME (ARDS) MARKET: BY TYPE, LIFELINE CURVE

FIGURE 38 U.S. ACUTE RESPIRATORY DISTRESS SYNDROME (ARDS) MARKET, BY TYPE, 2022

FIGURE 39 U.S. ACUTE RESPIRATORY DISTRESS SYNDROME (ARDS) MARKET: BY TYPE, 2023-2030 (USD MILLION)

FIGURE 40 U.S. ACUTE RESPIRATORY DISTRESS SYNDROME (ARDS) MARKET: BY TYPE, CAGR (2023-2030)

FIGURE 41 U.S. ACUTE RESPIRATORY DISTRESS SYNDROME (ARDS) MARKET: BY TYPE, LIFELINE CURVE

FIGURE 42 CHINA ACUTE RESPIRATORY DISTRESS SYNDROME (ARDS) MARKET, BY TYPE, 2022

FIGURE 43 CHINA ACUTE RESPIRATORY DISTRESS SYNDROME (ARDS) MARKET: BY TYPE, 2023-2030 (USD MILLION)

FIGURE 44 CHINA ACUTE RESPIRATORY DISTRESS SYNDROME (ARDS) MARKET: BY TYPE, CAGR (2023-2030)

FIGURE 45 CHINA ACUTE RESPIRATORY DISTRESS SYNDROME (ARDS) MARKET: BY TYPE, LIFELINE CURVE

FIGURE 46 JAPAN ACUTE RESPIRATORY DISTRESS SYNDROME (ARDS) MARKET, BY TYPE, 2022

FIGURE 47 JAPAN ACUTE RESPIRATORY DISTRESS SYNDROME (ARDS) MARKET: BY TYPE, 2023-2030 (USD MILLION)

FIGURE 48 JAPAN ACUTE RESPIRATORY DISTRESS SYNDROME (ARDS) MARKET: BY TYPE, CAGR (2023-2030)

FIGURE 49 JAPAN ACUTE RESPIRATORY DISTRESS SYNDROME (ARDS) MARKET: BY TYPE, LIFELINE CURVE

FIGURE 50 EUROPE ACUTE RESPIRATORY DISTRESS SYNDROME (ARDS) MARKET, BY ROUTE OF ADMINISTRATION, 2022

FIGURE 51 EUROPE ACUTE RESPIRATORY DISTRESS SYNDROME (ARDS) MARKET: BY ROUTE OF ADMINISTRATION, 2023-2030 (USD MILLION)

FIGURE 52 EUROPE ACUTE RESPIRATORY DISTRESS SYNDROME (ARDS) MARKET: BY ROUTE OF ADMINISTRATION, CAGR (2023-2030)

FIGURE 53 EUROPE ACUTE RESPIRATORY DISTRESS SYNDROME (ARDS) MARKET: BY ROUTE OF ADMINISTRATION, LIFELINE CURVE

FIGURE 54 U.S. ACUTE RESPIRATORY DISTRESS SYNDROME (ARDS) MARKET, BY ROUTE OF ADMINISTRATION, 2022

FIGURE 55 U.S. ACUTE RESPIRATORY DISTRESS SYNDROME (ARDS) MARKET: BY ROUTE OF ADMINISTRATION, 2023-2030 (USD MILLION)

FIGURE 56 U.S. ACUTE RESPIRATORY DISTRESS SYNDROME (ARDS) MARKET: BY ROUTE OF ADMINISTRATION, CAGR (2023-2030)

FIGURE 57 U.S. ACUTE RESPIRATORY DISTRESS SYNDROME (ARDS) MARKET: BY ROUTE OF ADMINISTRATION, LIFELINE CURVE

FIGURE 58 CHINA ACUTE RESPIRATORY DISTRESS SYNDROME (ARDS) MARKET, BY ROUTE OF ADMINISTRATION, 2022

FIGURE 59 CHINA ACUTE RESPIRATORY DISTRESS SYNDROME (ARDS) MARKET: BY ROUTE OF ADMINISTRATION, 2023-2030 (USD MILLION)

FIGURE 60 CHINA ACUTE RESPIRATORY DISTRESS SYNDROME (ARDS) MARKET: BY ROUTE OF ADMINISTRATION, CAGR (2023-2030)

FIGURE 61 CHINA ACUTE RESPIRATORY DISTRESS SYNDROME (ARDS) MARKET: BY ROUTE OF ADMINISTRATION, LIFELINE CURVE

FIGURE 62 JAPAN ACUTE RESPIRATORY DISTRESS SYNDROME (ARDS) MARKET, BY ROUTE OF ADMINISTRATION, 2022

FIGURE 63 JAPAN ACUTE RESPIRATORY DISTRESS SYNDROME (ARDS) MARKET: BY ROUTE OF ADMINISTRATION, 2023-2030 (USD MILLION)

FIGURE 64 JAPAN ACUTE RESPIRATORY DISTRESS SYNDROME (ARDS) MARKET: BY ROUTE OF ADMINISTRATION, CAGR (2023-2030)

FIGURE 65 JAPAN ACUTE RESPIRATORY DISTRESS SYNDROME (ARDS) MARKET: BY ROUTE OF ADMINISTRATION, LIFELINE CURVE

FIGURE 66 EUROPE ACUTE RESPIRATORY DISTRESS SYNDROME (ARDS) MARKET, BY END USER, 2022

FIGURE 67 EUROPE ACUTE RESPIRATORY DISTRESS SYNDROME (ARDS) MARKET: BY END USER, 2023-2030 (USD MILLION)

FIGURE 68 EUROPE ACUTE RESPIRATORY DISTRESS SYNDROME (ARDS) MARKET: BY END USER, CAGR (2023-2030)

FIGURE 69 EUROPE ACUTE RESPIRATORY DISTRESS SYNDROME (ARDS) MARKET: BY END USER, LIFELINE CURVE

FIGURE 70 U.S. ACUTE RESPIRATORY DISTRESS SYNDROME (ARDS) MARKET, BY END USER, 2022

FIGURE 71 U.S. ACUTE RESPIRATORY DISTRESS SYNDROME (ARDS) MARKET: BY END USER, 2023-2030 (USD MILLION)

FIGURE 72 U.S. ACUTE RESPIRATORY DISTRESS SYNDROME (ARDS) MARKET: BY END USER, CAGR (2023-2030)

FIGURE 73 U.S. ACUTE RESPIRATORY DISTRESS SYNDROME (ARDS) MARKET: BY END USER, LIFELINE CURVE

FIGURE 74 CHINA ACUTE RESPIRATORY DISTRESS SYNDROME (ARDS) MARKET, BY END USER, 2022

FIGURE 75 CHINA ACUTE RESPIRATORY DISTRESS SYNDROME (ARDS) MARKET: BY END USER, 2023-2030 (USD MILLION)

FIGURE 76 CHINA ACUTE RESPIRATORY DISTRESS SYNDROME (ARDS) MARKET: BY END USER, CAGR (2023-2030)

FIGURE 77 CHINA ACUTE RESPIRATORY DISTRESS SYNDROME (ARDS) MARKET: BY END USER, LIFELINE CURVE

FIGURE 78 JAPAN ACUTE RESPIRATORY DISTRESS SYNDROME (ARDS) MARKET, BY END USER, 2022

FIGURE 79 JAPAN ACUTE RESPIRATORY DISTRESS SYNDROME (ARDS) MARKET: BY END USER, 2023-2030 (USD MILLION)

FIGURE 80 JAPAN ACUTE RESPIRATORY DISTRESS SYNDROME (ARDS) MARKET: BY END USER, CAGR (2023-2030)

FIGURE 81 JAPAN ACUTE RESPIRATORY DISTRESS SYNDROME (ARDS) MARKET: BY END USER, LIFELINE CURVE

FIGURE 82 EUROPE ACUTE RESPIRATORY DISTRESS SYNDROME (ARDS) MARKET, BY DISTRIBUTION CHANNEL, 2022

FIGURE 83 EUROPE ACUTE RESPIRATORY DISTRESS SYNDROME (ARDS) MARKET: BY DISTRIBUTION CHANNEL, 2023-2030 (USD MILLION)

FIGURE 84 EUROPE ACUTE RESPIRATORY DISTRESS SYNDROME (ARDS) MARKET: BY DISTRIBUTION CHANNEL, CAGR (2023-2030)

FIGURE 85 EUROPE ACUTE RESPIRATORY DISTRESS SYNDROME (ARDS) MARKET: BY DISTRIBUTION CHANNEL, LIFELINE CURVE

FIGURE 86 U.S. ACUTE RESPIRATORY DISTRESS SYNDROME (ARDS) MARKET, BY DISTRIBUTION CHANNEL, 2022

FIGURE 87 U.S. ACUTE RESPIRATORY DISTRESS SYNDROME (ARDS) MARKET: BY DISTRIBUTION CHANNEL, 2023-2030 (USD MILLION)

FIGURE 88 U.S. ACUTE RESPIRATORY DISTRESS SYNDROME (ARDS) MARKET: BY DISTRIBUTION CHANNEL, CAGR (2023-2030)

FIGURE 89 U.S. ACUTE RESPIRATORY DISTRESS SYNDROME (ARDS) MARKET: BY DISTRIBUTION CHANNEL, LIFELINE CURVE

FIGURE 90 CHINA ACUTE RESPIRATORY DISTRESS SYNDROME (ARDS) MARKET, BY DISTRIBUTION CHANNEL, 2022

FIGURE 91 CHINA ACUTE RESPIRATORY DISTRESS SYNDROME (ARDS) MARKET: BY DISTRIBUTION CHANNEL, 2023-2030 (USD MILLION)

FIGURE 92 CHINA ACUTE RESPIRATORY DISTRESS SYNDROME (ARDS) MARKET: BY DISTRIBUTION CHANNEL, CAGR (2023-2030)

FIGURE 93 CHINA ACUTE RESPIRATORY DISTRESS SYNDROME (ARDS) MARKET: BY DISTRIBUTION CHANNEL, LIFELINE CURVE

FIGURE 94 JAPAN ACUTE RESPIRATORY DISTRESS SYNDROME (ARDS) MARKET, BY DISTRIBUTION CHANNEL, 2022

FIGURE 95 JAPAN ACUTE RESPIRATORY DISTRESS SYNDROME (ARDS) MARKET: BY DISTRIBUTION CHANNEL, 2023-2030 (USD MILLION)

FIGURE 96 JAPAN ACUTE RESPIRATORY DISTRESS SYNDROME (ARDS) MARKET: BY DISTRIBUTION CHANNEL, CAGR (2023-2030)

FIGURE 97 JAPAN ACUTE RESPIRATORY DISTRESS SYNDROME (ARDS) MARKET: BY DISTRIBUTION CHANNEL, LIFELINE CURVE

FIGURE 98 EUROPE ACUTE RESPIRATORY DISTRESS SYNDROME (ARDS) MARKET: SNAPSHOT (2022)

FIGURE 99 EUROPE ACUTE RESPIRATORY DISTRESS SYNDROME (ARDS) MARKET: BY COUNTRY (2022)

FIGURE 100 EUROPE ACUTE RESPIRATORY DISTRESS SYNDROME (ARDS) MARKET: BY COUNTRY (2023 & 2030)

FIGURE 101 EUROPE ACUTE RESPIRATORY DISTRESS SYNDROME (ARDS) MARKET: BY COUNTRY (2022 & 2030)

FIGURE 102 EUROPE ACUTE RESPIRATORY DISTRESS SYNDROME (ARDS) MARKET: CAUSE (2023-2030)

FIGURE 103 U.S. ACUTE RESPIRATORY DISTRESS SYNDROME (ARDS) MARKET: COMPANY SHARE 2022 (%)

FIGURE 104 EUROPE ACUTE RESPIRATORY DISTRESS SYNDROME (ARDS) MARKET: COMPANY SHARE 2022 (%)

FIGURE 105 JAPAN ACUTE RESPIRATORY DISTRESS SYNDROME (ARDS) MARKET: COMPANY SHARE 2022 (%)

FIGURE 106 CHINA ACUTE RESPIRATORY DISTRESS SYNDROME (ARDS) MARKET: COMPANY SHARE 2022 (%)

자세한 정보 보기 Right Arrow

연구 방법론

데이터 수집 및 기준 연도 분석은 대규모 샘플 크기의 데이터 수집 모듈을 사용하여 수행됩니다. 이 단계에는 다양한 소스와 전략을 통해 시장 정보 또는 관련 데이터를 얻는 것이 포함됩니다. 여기에는 과거에 수집한 모든 데이터를 미리 검토하고 계획하는 것이 포함됩니다. 또한 다양한 정보 소스에서 발견되는 정보 불일치를 검토하는 것도 포함됩니다. 시장 데이터는 시장 통계 및 일관된 모델을 사용하여 분석하고 추정합니다. 또한 시장 점유율 분석 및 주요 추세 분석은 시장 보고서의 주요 성공 요인입니다. 자세한 내용은 분석가에게 전화를 요청하거나 문의 사항을 드롭하세요.

DBMR 연구팀에서 사용하는 주요 연구 방법론은 데이터 마이닝, 시장에 대한 데이터 변수의 영향 분석 및 주요(산업 전문가) 검증을 포함하는 데이터 삼각 측량입니다. 데이터 모델에는 공급업체 포지셔닝 그리드, 시장 타임라인 분석, 시장 개요 및 가이드, 회사 포지셔닝 그리드, 특허 분석, 가격 분석, 회사 시장 점유율 분석, 측정 기준, 글로벌 대 지역 및 공급업체 점유율 분석이 포함됩니다. 연구 방법론에 대해 자세히 알아보려면 문의를 통해 업계 전문가에게 문의하세요.

사용자 정의 가능

Data Bridge Market Research는 고급 형성 연구 분야의 선두 주자입니다. 저희는 기존 및 신규 고객에게 목표에 맞는 데이터와 분석을 제공하는 데 자부심을 느낍니다. 보고서는 추가 국가에 대한 시장 이해(국가 목록 요청), 임상 시험 결과 데이터, 문헌 검토, 재생 시장 및 제품 기반 분석을 포함하도록 사용자 정의할 수 있습니다. 기술 기반 분석에서 시장 포트폴리오 전략에 이르기까지 타겟 경쟁업체의 시장 분석을 분석할 수 있습니다. 귀하가 원하는 형식과 데이터 스타일로 필요한 만큼 많은 경쟁자를 추가할 수 있습니다. 저희 분석가 팀은 또한 원시 엑셀 파일 피벗 테이블(팩트북)로 데이터를 제공하거나 보고서에서 사용 가능한 데이터 세트에서 프레젠테이션을 만드는 데 도움을 줄 수 있습니다.

자주 묻는 질문

The Europe, U.S., China, and Japan Acute Respiratory Distress Syndrome (ARDS) Market is projected to grow at a CAGR of 9.9% during the forecast period by 2030.
The Europe, U.S., China, and Japan Acute Respiratory Distress Syndrome (ARDS) Market is segmented on the basis of cause, type, route of administration, end-user, and distribution channel.
The major players in the Europe, U.S., China, and Japan Acute Respiratory Distress Syndrome (ARDS) Market are Drägerwerk AG & Co. KGaA, Fisher & Paykel Healthcare Limited., LivaNova PLC, Gilead Sciences, Inc., Fresenius SE & Co. KGaA, Besmed Health Business Corp., Armstrong Medical, Smiths Medical, etc.
The countries covered in the Europe, U.S., China, and Japan Acute Respiratory Distress Syndrome (ARDS) Market are U.S., Japan, China, Germany, U.K., Italy, France, Spain, Switzerland, Russia, Turkey, Hungary, Lithuania, Austria, Ireland, Norway, Poland, Netherlands and the Rest of Europe.